A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
ConditionPsoriasis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorInventisBio Co., Ltd
About this trial
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
Within normal ranges of laboratory assessments
Disqualifiers
Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Trial design
Design model
Parallel
Treatments tested in this trial
D-2570 Tablet
DrugActive Treatment
Placebo Tablets
DrugIdentical Tablet
Treatment groups
75 Participants
are divided into 3 treatment groupsGroup A: D-2570 low doseActive comparator 1 intervention
Group B: D-2570 High DoseActive comparator 1 intervention
Group C: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Improvement in PASI-90
Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Time frame
Assessment completed after 12 weeks of treatment/placeboSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov